Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesFRA:BUWA +0.85%75 EV-to-EBIT is 23.24 as of Aug. 12, 2026, which is 432% above its 10-year median of 4.37. GuruFocus rates FRA:BUWA with a GF Score™ of 75/100 and a GF Value™ of €272.26 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 59.53% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's EV-to-EBIT or its related term are showing as below:
FRA:BUWA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -81.66 Med: 4.37 Max: 173.4
Current: 23
During the past 13 years, the highest EV-to-EBIT of Bio-Rad Laboratories was 173.40. The lowest was -81.66. And the median was 4.37.
FRA:BUWA's EV-to-EBIT is ranked worse than 59.53% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.215
vs FRA:BUWA: 23.00
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bio-Rad Laboratories's Enterprise Value for the quarter that ended in Jun. 2026 was €6,665 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories EV-to-EBIT Related Terms
Bio-Rad Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, GMED: EV-to-EBIT Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBIT falls into.
Bio-Rad Laboratories's current Enterprise Value is €7,951 Mil.
Bio-Rad Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €342 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a EV-to-EBIT of 23.24 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio-Rad Laboratories and its competitors. This is 432% above median its historical median of 4.37. According to the industry distribution chart, Bio-Rad Laboratories ranks #281 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 59.5%.
Is Bio-Rad Laboratories' EV-to-EBIT too high?
Bio-Rad Laboratories' current EV-to-EBIT of 23.24 is 432% above median its 10-year median of 4.37. The Medical Devices & Instruments industry median EV-to-EBIT is 19.22. Bio-Rad Laboratories' value of 23.24 is 20.9% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #281 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EV-to-EBIT compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #281 out of 472 companies for EV-to-EBIT. This places Bio-Rad Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 19.22. Bio-Rad Laboratories' value of 23.24 is 20.9% above this benchmark. While the company's 10-year median is 4.37 vs. the industry median of 19.22, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.22, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current EV-to-EBIT of 23.24 is 20.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current EV-to-EBIT is 23.24, which is 432% above median its own 10-year median of 4.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €272.26, compared to a current price of €307.80 — trading 13.1% above its estimated fair value. The current EV-to-EBIT is 23.24, which is 432% above median its 10-year median of 4.37 and 20.9% above the Medical Devices & Instruments industry median of 19.22. Bio-Rad Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current EV-to-EBIT is 23.24 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €307.80 is trading 13.1% above its estimated GF Value™ of €272.26.
GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.
Key valuation signals for FRA:BUWA:
EV-to-EBIT: 23.24 (432% above median its 10-year median of 4.37)
GF Value™: €272.26 vs. price of €307.80 (13.1% above fair value)
Industry Position: 20.9% above the Medical Devices & Instruments median (#281 of 472)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
75GF Score
Get the complete analysis for FRA:BUWA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
